Hydroxycarbamide Tablets Application Scope

Agatharesidase Alfa is used in the treatment of Fabry disease (alpha-galactosidase A deficiency) as a new potent drug and long-term enzyme replacement therapy. It is indicated for use in adults, children and adolescents. Safety and efficacy in children 0-6 years of age have not been established.

Hydroxycarbamide Tablets Features

Ingredients: Hydroxyurea

Characteristics: Treatment of chronic granulocytic leukemia (CML)

Specification: 0.5g

Packing specification: 0.5g*100 tablets/bottle.

Storage: Shielded from light and kept sealed.

Effective period: 36 months

Execution Standard: Chinese Pharmacopoeia 2010 Edition, Second Part

Approval number: State Drug License H37021289

Revision date According to the latest drug instructions.

Manufacturer: Qiluanti Pharmaceuticals

Hydroxycarbamide Tablets User’s Guide

Dosage and administration: Oral, CML 20-60mg/kg per day, twice a week, 6 weeks as a course of treatment; head and neck cancer, cervical squamous carcinoma, etc. Sensitive times 80mg/kg, every three days, need to be combined with radiotherapy.

Adverse reactions: myelosuppression is a dose-limiting toxicity, which can cause leukopenia and thrombocytopenia, and can be recovered in 1~2 weeks after stopping the drug; sometimes gastrointestinal reactions, and testicular atrophy and teratogenicity have been reported.

Restrictions on the use of hydroxycarbamide tablets

Contraindications: chickenpox, herpes zoster and various serious infections are prohibited.

Precautions: Fluid intake should be increased appropriately when taking this product to increase urine output and excretion of uric acid. Regularly monitor white blood cells, platelets, blood urea nitrogen, uric acid and inosine concentration.

Interactions of Hydroxycarbamide Tablets

This product has a depressant effect on the central nervous system, so be careful with barbiturates, tranquilizers, and narcotics when using this product. Inform your doctor of all medications you are using before starting treatment.

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.